This stock is a great choice for cautious and aggressive investors.

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the morning session after the company ...

As support from the U.S. government has evaporated, Moderna is leaning on an old ally to carry plans for its prospective mRNA ...

In the latest trading session, Moderna (MRNA) closed at $30.41, marking a -2.38% move from the previous day. This move lagged the S&P 500's daily loss of 0.14%. On the other hand, the Dow registered a ...

Moderna, Inc. has rallied ~23%, but rated a Sell due to deteriorating fundamentals. Learn more about MRNA stock here.

Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research ...

Since that moment, Moderna has taken steps to pave the path to long-term growth -- from cutting costs to focusing on its vast pipeline. Considering the full picture, now, with the stock down 80% over ...

Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental ...

Get the latest Moderna (MRNA) stock analysis: balanced risk-reward, new vaccine launches, and pipeline insights. See why we ...

NEXSPIKE is Moderna’s third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine) mNEXSPIKE will be available in the ...

The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government ...

Both vaccines work. But Pfizer requires a longer waiting period before the vaccine kicks in, while Moderna has stronger side effects.